Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.
Shanghai-based drug developer Zai Lab shares surged $9.93 (55%) to $27.93 on its first day of trading. Through an initial public offering on Nasdaq, the company issued 8.3m American Depository Shares (ADS) at $18 each to raise $150m. Reflecting the strong interest in Chinese drug development, the offering was increased from the previously planned $100m offering.
Founded in 2013 by serial entrepreneur Samantha Du, Shanghai Zai Lab Ltd. is now a rising star among new...
Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
US green light will further expand sales of the prostate cancer blockbuster.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
